Beta Bionics Announces Participation at Upcoming Investor Conferences

IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):

• Wolfe Research 7th Annual Healthcare Conference on Tuesday, November 18, 2025 at 2:00pm
• Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30pm

The presentations will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the events.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Investor Relations:Blake BeberHead of Investor Relationsir@betabionics.com

Media and Public Relations: Karen HynesVice President of Marketingmedia@betabionics.com

Source: Beta Bionics, Inc.